Evidence map›Paper›PMID 36033279›Full record

ArticleHeliyon2022

A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated

Freek Haerkens, Charlotte Kikken, Laurens Kirkels, Monique van Amstel, Willemijn Wouters, Els van Doornmalen, Christof Francke, Samantha Hughes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Maackiain Mimics Caloric Restriction throughInternational journal of molecular sciences · 2023
    Article
  3. Article
  4. The Effectiveness ofVascular health and risk management · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Freek HaerkensBioCentre, HAN University of Applied Sciences, 6525EM, Nijmegen, the Netherlands.
Charlotte KikkenBioCentre, HAN University of Applied Sciences, 6525EM, Nijmegen, the Netherlands.
Laurens KirkelsBioCentre, HAN University of Applied Sciences, 6525EM, Nijmegen, the Netherlands.
Monique van AmstelPivot Park Screening Centre, 5349AB, Oss, the Netherlands.
Willemijn WoutersPivot Park Screening Centre, 5349AB, Oss, the Netherlands.
Els van DoornmalenPivot Park Screening Centre, 5349AB, Oss, the Netherlands.
Christof FranckeBioCentre, HAN University of Applied Sciences, 6525EM, Nijmegen, the Netherlands.
Samantha HughesBioCentre, HAN University of Applied Sciences, 6525EM, Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is one of the most common global health problems for all age groups with obese people at risk of a variety of associated health complications. Consequently, there is a need to develop new therapies that lower body fat without the side effects. However, obesity is a complex and systemic disease, so that

Indexed as

C. elegansHigh-throughput screeningObesityPrestwick chemical libraryRepurposing drugs

Identifiers

PMID36033279
PMCPMC9399480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.